Cowen analyst Yaron Werber lowered the firm’s price target on Amgen to $289 from $307 and keeps an Outperform rating on the shares. The analyst said Q4 beat on revs/EPS despite multiple legacy franchises looking light while 23 guidance looks appropriately conservative to account for biosimilar competition.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMGN:
